103 related articles for article (PubMed ID: 17116021)
1. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans.
Yao C; Doose DR; Novak G; Bialer M
Epilepsia; 2006 Nov; 47(11):1822-9. PubMed ID: 17116021
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults.
Chien S; Bialer M; Solanki B; Verhaeghe T; Doose DR; Novak G; Yao C
Epilepsia; 2006 Nov; 47(11):1830-40. PubMed ID: 17116022
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly.
Levy R; Ragueneau-Majlessi I; Solanki B; Zannikos P; Yao C; Novak G
Epilepsy Res; 2008 Mar; 79(1):22-30. PubMed ID: 18280116
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
6. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
Lin CC; Philips L; Xu C; Yeh LT
J Clin Pharmacol; 2004 Mar; 44(3):265-75. PubMed ID: 14973309
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
13. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
[TBL] [Abstract][Full Text] [Related]
14. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
[TBL] [Abstract][Full Text] [Related]
15. An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid.
Chien S; Yao C; Mertens A; Verhaeghe T; Solanki B; Doose DR; Novak G; Bialer M
Epilepsia; 2007 Jul; 48(7):1328-38. PubMed ID: 17381436
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
Darwish M; Chang S; Hellriegel ET
Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
[TBL] [Abstract][Full Text] [Related]
17. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
[TBL] [Abstract][Full Text] [Related]
18. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose.
Yamaya H; Yoshida K; Kuritani J; Yonezawa J; Tsuda M; Shindo T; Nagayama S; Buzdar AU
J Clin Pharm Ther; 2005 Oct; 30(5):459-70. PubMed ID: 16164493
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
